1 **Title:** Conditional Protein Rescue (CPR) by Binding-Induced Protective Shielding

2

3 **Author affiliation:** Andrew S. Gaynor¹ and Wilfred Chen^{1,*}

4 1. Department of Chemical and Biomolecular Engineering, University of Delaware, 150
5 Academy St., Newark, DE 19716

6 **Corresponding author:** Wilfred Chen; Department of Chemical and Biomolecular
7 Engineering, University of Delaware, 150 Academy St., Newark, DE 19716; telephone:
8 (302)831-6327; wilfred@udel.edu *To whom correspondence should be addressed. E-
9 mail: wilfred@udel.edu

1 **Abstract**

2 An effective method to modulate the stability of proteins is essential to biological
3 research. Herein, we describe a new technology that allows conditional stabilization of
4 proteins based on masking of a degron tag by a specific intracellular protein cue. A
5 target protein is fused to a degron tag and an affinity sensor domain. When the sensor
6 detects its target protein, the degron is effectively concealed and the target protein is
7 rescued. By introducing nanobodies as the sensor, we allow for virtually any endogenous
8 protein to be targeted. In a model system using yeast cytosine deaminase, we
9 demonstrate low cell death background yet maintain the ability to elicit strong activation
10 and prodrug-mediated cell killing using GFP as the rescue protein. The flexibility in
11 choosing different masking targets provides a straightforward method to generalize the
12 strategy for conditional protein rescue in a wide range of biological contexts, including
13 oncoprotein detection.

1 **Introduction**

2 Conditional control of protein levels remains elusive for many biological applications.
 3 RNA interference (RNAi) destroys mRNA, but it can frequently be off-target or partially
 4 potent (Sigoillot and King, 2011). While small molecule-responsive transcriptional
 5 switches are frequently used to regulate mRNA levels, the overall dynamic is limited by
 6 the half-life of the target protein (Battle et al., 2015; Vogel and Marcotte, 2012; Wu et al.,
 7 2013). Another common method is the fusion of a degradation domain (DD) to a protein
 8 of interest (POI) (Li et al., 1998), which drastically reduces its half-life and allows faster
 9 fluctuations in the intracellular level (Mei et al., 2018; Sjaastad et al., 2018). As we
 10 recently reviewed (Chen et al., 2019), while several approaches can modulate protein
 11 degradation in response to a small molecule (Chung et al., 2015; Iwamoto et al., 2010;
 12 Lau et al., 2010), they do not allow protein concentration control in response to native
 13 cellular environments. Ideally, a modular platform that combines rapid protein turnover
 14 by DDs with temporal and autonomous responsiveness to cellular environments will
 15 greatly expand our ability to generalize the strategy for conditional protein rescue (CPR)
 16 in a wide range of biological contexts.

17 Coordinated degradation of cyclins is a key mechanism to ensure correct
 18 progression through the cell cycle (Harper et al., 2002; Morgan, 1997; Sherr and Roberts,
 19 1999). This exquisite control between accumulation and depletion of cyclins is tightly
 20 regulated by changes in cellular protein information, suggesting a possible framework for
 21 CPR. One potential strategy is based on the Ac/N-End Rule pathway used for protein
 22 quality control, which recognizes and targets certain N α -terminally acetylated residues for
 23 degradation (Oh et al., 2017; Shemorry et al., 2013; Zhang et al., 2010). Remarkably, the

same acetylated residue is also necessary for proper interaction with cellular chaperones, which sterically shield the degradation domain and preserve properly folded proteins. The intriguing ability to shield the DD from initiating degradation has inspired the design of a new generation of artificial protein stability switches for conditional degradation. Insertion of a DD into the J α -helix successfully shielded the DD-J α -helix peptide within the LOV domain and arrested degradation. Irradiation with blue light unmasked the J α -helix and restored degradation (Renicke et al., 2013). Similarly, a DD placed between two proteins was only activated upon release by protease cleavage (Jungbluth et al., 2010; Taxis et al., 2009). While these reports represent a first step towards CPR, they are unable to couple endogenous cellular cues to modulate degradation.

We sought to increase the practicality of CPR by using cellular protein cues to provide masking and unmasking of DDs. In this design, a small sensor domain is appended to the DD. When a binding target is present, the DD is effectively concealed, and the target protein is rescued (Fig. 1A). We demonstrated that effective CPR can be executed using both covalent SpyTag/SpyCatcher conjugation and non-covalent nanobody/antigen interaction. Selective rescue of the yeast cytosine deaminase enabled strong prodrug activation and targeted cell killing.

1

2

3 **Figure 1. Conditional protein rescue (CPR) via masking the DD.** a) The DD (blue squiggle) contains a
4 small sensor domain (purple triangle) fused to its C-terminus. In the absence of the corresponding binding
5 target to the sensor, the POI (yellow hexagon) is recruited to the proteasome via DD interaction (red
6 symbol) and degradation proceeds (left). Interaction with the target (green cut-out circle) conceals the DD
7 from the proteasomal recruitment, and the POI is rescued from degradation (right). b) YFP is fused to the
8 cODC1 DD and SpyTag (sensor) and co-expressed with mCherry as a transfection marker. YFP is
9 degraded by proteasome recognition of cODC1, and mCherry remains. c) When mCherry is fused to the
10 SpyCatcher (target), the SpyTag sensor recruits SpyCatcher-miRFP670, sterically concealing cODC1 and
11 rescuing YFP by CPR.

1 **Results**

2 **Conditional protein rescue by covalent SpyTag/SpyCatcher conjugation**

3 To evaluate the feasibility of CPR, we first utilized the SpyCatcher and SpyTag system,
 4 which provides the most stable *in vivo* interaction because of covalent conjugation
 5 (Zakeri et al., 2012). A well-characterized synthetic cODC1-like C-degron tag was used
 6 as an effective DD with kinetics that allow for rescue to occur (Renicke et al., 2013). By
 7 fusing the DD-SpyTag to a fluorescent reporter, we generated YFP-cODC1-SpyTag, an
 8 unstable complex that can be rescued by SpyCatcher. We employed mCherry as an
 9 orthogonal transfection reporter (Fig. 1B). Both the YFP fusion and mCherry were
 10 expressed under one promotor by use of a polycistronic viral T2A self-cleaving sequence
 11 (Holst et al., 2006; Szymczak et al., 2004). To induce rescue of YFP, SpyCatcher was
 12 fused to mCherry for easy tracking (Fig. 1C).

13 To evaluate the rescue efficiency, HeLa cells were transfected with SpyCatcher-
 14 mCherry:T2A:YFP-cODC1-SpyTag or the control, mCherry:T2A:YFP-cODC1-SpyTag,
 15 without SpyCatcher. Expression of both proteins was tracked by fluorescent microscopy
 16 and western blot over 60 h. Western blot analysis (Fig. 2A) demonstrated that mCherry
 17 was detected consistently in both constructs roughly 15 h post-transfection. YFP
 18 gradually disappeared in cells expressing only mCherry, while a strong band
 19 corresponding only to the ligated YFP products was detected for cells expressing
 20 SpyCatcher-mCherry. The absence of any un-ligated YFP with SpyCatcher-mCherry co-
 21 expression highlights that ligation between SpyTag and SpyCatcher is solely responsible
 22 for YFP rescue due to shielding of the DD (Fig. 2A, top right box). This is further

- 1 supported by the fluorescent images (Supplementary Fig. 1) demonstrating efficient YFP
- 2 rescue due to DD shielding by SpyTag-SpyCatcher ligation.

3 **Figure 2. YFP rescue from cODC1-mediated degradation via SpyTag-SpyCatcher interaction.** a)

4 Western blotting of HeLa cell lysate. Expression of YFP and mCherry/mCherry-SpyCatcher were by their

5 respective antibodies. The upward shift in the protein size for the mcherry-SpyCatcher samples was the

6 result of SpyTag-SpyCatcher conjugation. b) Flow cytometry quantification of YFP enhancement by CPR.

7 miRFP670, a near-infrared fluorescent protein with a completely orthogonal signal to YFP on the flow

8 cytometer, was used in place of mcherry. Fold enhancement is YFP signal normalized to miRFP670

9 expression in the SpyCatcher-miRFP670 fusion sample relative to the control with no SpyCatcher

10 expression. Error bars represent 95% confidence intervals.

1 To quantify CPR more accurately, miRFP670 — a near-infrared, monomeric,
2 fluorescent protein with a completely orthogonal signal to YFP on the flow cytometer
3 (Shcherbakova et al., 2016) — was fused similarly to mCherry to generate SpyCatcher-
4 miRFP670:T2A:YFP-cODC1-SpyTag and the control, miRFP670:T2A:YFP-cODC1-
5 SpyTag. Flow cytometry showed that CPR enhancement increased throughout the entire
6 time course, with roughly 7.5-fold increase in the YFP signal after 60 h (Fig. 2B).
7 Western blots confirmed a similar size increase as a result of the covalent conjugation
8 between SpyCatcher and SpyTag (Supplementary Fig. 2).

9

10 **Use of non-covalent interactions for CPR**

11 Although CRP was correctly executed using covalent conjugation between SpyTag and
12 SpyCatcher, most intracellular interactions are non-covalent in nature. To show that non-
13 covalent interaction can also be used to provide similar shielding effects, we replaced the
14 SpyTag/SpyCatcher pair with the well-known Src homology 3 (SH3) domain and its
15 corresponding binding ligand, wLig ($k_D = 10 \mu M$) (Dueber et al., 2007; Li, 2005). A
16 similar shielding effect was observed albeit at reduced efficiencies, confirming that even
17 a weak non-covalent interaction is sufficient to provide adequate masking of the DD
18 (Supplementary Fig. 3). Again, no rescue was observed when the SH3 domain is absent,
19 highlighting again the importance of specific interaction for proper DD masking
20 (Supplementary Fig. 3).

21 In order to adapt this technology towards more relevant cellular targets, a small,
22 monomeric sensor capable of interacting with endogenous proteins with high specificity
23 is required. Camel single-domain antibody fragments, or nanobodies, are ideal because

of their relative small size (~13kDa) and the ability to generate high-affinity nanobodies for virtually any protein target (Kubala et al., 2010; Saerens et al., 2005). To investigate whether the degradation phenotype could be preserved even after addition of a nanobody near the DD, an anti-GFP nanobody (GBP1, $k_D \sim 1$ nM) was first fused to the C-terminus of an miRFP670-cODC1 fusion (Fig. 3A). Unlike conjugation of a SpyCatcher-fusion onto an adjacent SpyTag to cOCD1, no masking of the DD was observed as virtually no miRFP670 signal was detected (Supplementary Fig. 4, left side). This is somewhat unexpected as a small structural nanobody was physically tethered next to the DD. We speculate that the steric masking of the DD may be size dependent. To test this hypothesis, we fused a larger maltose-binding protein (MBP; 43 kDa) to the C-terminus of GBP1. This resulted in improved miRFP670 signal (Supplementary Fig. 4, right side), an outcome consistent with the proposed enhanced DD masking and miRFP670 rescue.

After establishing that a small nanobody GBP1 can be fused after the DD without impacting degradation, we next investigated whether protein rescue could be attained based on GBP1 and GFP interaction. In the presence of BFP, which could not associate with GBP1, miRFP670 was still efficiently degraded. In contrast, expression of GFP efficiency rescued miRFP670 from degradation due to GFP shielding of the DD (Fig. 3B and Supplementary Fig. 4). Somewhat surprisingly, GFP failed to induce as effective CPR when we used GBP6, a nanobody that binds GFP at a different epitope than GBP1 (Tang et al., 2013), suggesting that interacting orientation, in addition to the size of the rescuing protein, is also important for CPR (Supplementary Fig. 5). These results provide the feasibility to repurpose nanobody-antigen interactions to elicit CPR for many different synthetic biology applications of practical interest.

Figure 3. Rescuing a POI using non-covalent nanobody-antigen interactions. a) miRFP670 is fused to the cODC1 DD and an anti-GFP nanobody (GBP1), which still maintains its inherently unstable feature. HeLa cells expressing miRFP670-cODC1-GBP1 were co-transfected with either BFP or GFP for CPR. Co-expression with BFP alone did not result in miRFP670 rescue due to a lack of interaction with GBP1, while co-expression with GFP restored miRFP670 signal due to DD masking. b) Flow cytometry quantification of miRFP670 fluorescence in the presence of BFP (grey) and GFP (blue) after 48 h. Inserts show fluorescent microscopy images of miRFP670 of each sample.

Engineering CPR for prodrug activation

One of the most pressing needs in cancer treatment is to distinguish cancer versus healthy cells. Prodrug targeting offers a layer of therapeutic control due to the innocuous nature

1 of prodrugs. Yeast cytosine deaminase (yCD) is a prodrug-converting enzyme (PCE) that
2 transforms the innocuous 5-fluorocytosine (5-FC) into the cytotoxic 5-fluorouracil (5-
3 FU), and it has been used successfully for the treatment of glioblastoma (Polak et al.,
4 1976; Zhang et al., 2014). Previously, we demonstrated the ability to regulate yCD
5 activity using a small molecule-dependent rescue system, but this approach lacked any
6 autonomous ability to distinguish cancer cells from healthy cells (Gaynor and Chen,
7 2017). To adapt CPR for prodrug targeting, yCD was used as the POI to test how well
8 this strategy can control 5-FC activation. GFP again served as a visually trackable
9 surrogate for a cancer-relevant protein. The ability to trigger cell death by 5-FU was used
10 to indicate the overall efficiency of the conditional PCE therapy. A dye that only crosses
11 the leaky cell membrane of dead cells was used as a visible indicator of cell viability. As
12 expected, 5-FU killed large quantities of cells regardless of GFP, while cell viability was
13 high when no drugs were administered (Fig. 4). When treated with 5-FC, only cells co-
14 expressing GFP were killed in similar quantities to those being treated directly with 5-FU
15 (Fig. 4). Although the degree of cell killing in the absence of GFP but with 5-FC is
16 slightly higher than cells without 5-FC addition (Fig. 4B), this undesired outcome can be
17 rectified by using a stronger degradation signal (*e.g.* UbL) or a combination of multiple
18 DDs.

19

Figure 4. Controlling yCD activity via protein-nanobody interaction-mediated rescue. a) Fluorescent images of a cell death dye. Presence of the dye (pink) indicates a dead cell. Cells die in large numbers in the presence of 5-FU. Cells are killed by 5-FC, the prodrug, only when GFP rescues yCD by stabilizing the DD-nanobody fusion. b) Quantification of all fluorescent images, normalizing NucRed Dead dye to BFP, the protein transfection marker. Cells were transfected and either treated with no drugs (No Treatment), 5-FC, or 5-FU ($n = 10$; * = $p < 0.05$; ** = $p < 0.01$; NS = no statistical significant difference).

Tuning CPR by using a stronger proteasome binding motif

We next sought to improve the design to eliminate the background further. Previously, it has been reported that an unstructured domain and a proteasomal targeting moiety are both necessary for efficient proteasomal degradation (Prakash et al., 2009). To determine

1 if our CPR design could block access to the unstructured cOCD1 domain in the presence
2 of a second proteasomal targeting moiety, we fused one copy of the ubiquitin-like (UbL)
3 domain to the N-terminus of YFP (Stack et al., 2000). UbL is derived from the Rad23
4 protein and has been shown to target its fusion partners directly to the proteasome more
5 effectively than the cODC1 tag (Elsasser et al., 2002; Yu et al., 2016). Fusing a UbL
6 domain to the N-terminus of YFP enhanced the overall degradation, demonstrating that
7 CPR can be tuned to achieve varying activation levels and signal to background ratios
8 (compare the disappearance of YFP bands in Fig. 5B with Fig. 2A). Neither fluorescent
9 microscopy (Fig. 5A and Supplementary Fig. 6) nor western blot (Fig. 5B) could detect
10 YFP in the absence of SpyCatcher-mCherry. Co-expression of SpyCatcher-mCherry was
11 again able to rescue YFP, although the rescued YFP level was lower than without the
12 UbL domain (Fig. 5A). The increase in protein degradation kinetics competes more
13 aggressively with the SpyTag-SpyCatcher reaction, resulting in less rescue. This result
14 highlights the modularity of our approach in adjusting signal background and rescue
15 intensity and its ability to conceal unstructured domains from a proteasome in a UbL-
16 tagged target.

17

Figure 5. Tuning YFP rescue using the stronger proteasome binding UbL domain to improve degradation kinetics. a) Quantification of fluorescent microscopy measuring YFP intensity normalized by mCherry intensity. Compared to designs without UbL (see Fig. 2), background YFP intensity was decreased (red line), but the ability of YFP to be rescued decreased as well (green line). The images show HeLa cells with the YFP signal (green) 9 h and 60 h post transfection. Error bars represent $\pm$ 95% confidence interval (n = 5). b) Western blotting of HeLa cell lysate. The UbL domain is effective in eliminating any detectable traces of YFP expression without rescue (lower left box). Co-expression with SpyCatcher rescued YFP from degradation (lower right box).

CPR for N-End Rule Degrons

Encouraged by the CPR results using the cOCD1 C-degron, we next turned our attention to the N-end rule protein degradation pathway. Because the N-end rule substrates are recognized by specific binding proteins known as N-recognins, which deliver these substrates to the 26S proteasome for destruction (Choi et al., 2010; Matta-Camacho et al., 2010), chaperones are able to protect their targets via steric interference (Zhang et al., 2010). We reasoned that expressing a sensing nanobody directly following a destabilizing N-terminus residue as a fusion to a POI should result in rescue when the corresponding nanobody's target is co-expressed.

To conduct CPR using an N-end rule degron, we relied upon the ubiquitin (Ub) fusion technique, in which Ub is added to the N-terminus of a POI. The Ub domain is subsequently cleaved by an endogenous deubiquitylase, exposing the desired N-terminus residue for destabilization (Bachmair et al., 1986). Using this strategy, we generated three Ub:X-GBP1-miRFP670 fusions, where X is the resulting N-terminal residue: methionine (M, half-life = 30 hr), leucine (L, half-life = 5.5 hr), or arginine (R, half-life = 1.0 hr) (Gonda et al., 1989). These constructs were co-expressed with either BFP or GFP. Co-expression of BFP resulted in weak miRFP670 fluorescence scaling to the reported half-lives of the N-terminus residues tested. In contrast, co-expressing with GFP resulted in a dramatic rescue of miRFP670, showing more fluorescence than rescuing with the cOCD1 degron (Fig. 6a and Supplementary Fig. 7). Due to its extremely low background yet high level of rescue, an Arg N-terminus degron elicited an unprecedented >50-fold increase in protein fluorescence. To ensure that CPR was not a phenomenon specific to GBP1 and GFP-mediated rescue, we replaced GBP1 with LaM4, a nanobody

1 that detects mCherry (Fridy et al., 2014), to create EGFP-cODC1-LaM4 and three
2 different Ub:X-LaM4-EGFP fusions. For all constructs, only co-expression with mCherry
3 resulted in higher EGFP fluorescence, and the N-end rule CPR outperformed C-end rule
4 (Supplementary Fig. 8).

5
6 **Figure 6. Rescuing protein by blocking N-end rule-mediated degradation.** a) When BFP is co-
7 expressed, miRFP670 rescue does not occur, and the residual fluorescence levels scale well with the
8 reported half-lives of proteins with the respective N-terminal amino acids. However, co-expression of GFP
9 resulted in a significant increase in miRFP670 fluorescence levels. Furthermore, fluorescence levels of
10 rescued protein are comparable regardless of which N-terminal amino acid is used. b) The fold
11 enhancement measured for each N-terminal amino acid is plotted as a function of the median miRFP670
12 fluorescence when co-expressed with GFP divided by the median when co-expressed with BFP

1 (background fluorescence). Each N-terminal amino acid noted some enhancement, with Arg measuring
2 more than 50x enhancement. Error bars represent a 95% confidence interval.

3 **CPR for the Detection of HPV-Positive Cells**

4 To illustrate the broader applicability of our CPR approach toward native protein
5 targets, we next extended our design to detect human papillomavirus (HPV)-positive
6 cells. HPV is a known oncovirus that mainly relies on two proteins to induce
7 carcinogenesis in cervical cells: E6, a major suppressor of apoptosis, and E7, a driver of
8 the cell cycle (Jansma et al., 2014; Moody and Laimins, 2010; Senba and Mori, 2012).
9 Using E7 as a HPV marker, we exploited nE7, a nanobody that detects E7 (Li et al.,
10 2019), to generate Ub:R-nE7-mCherry to execute CPR. We transfected this construct and
11 the control Ub:R-GBP1-mCherry into both HPV-positive HeLa cells and HPV-negative
12 HEK293T cells. The HEK293T cells showed similar low levels of mCherry fluorescence
13 regardless of which nanobody was used to perform CPR (Fig. 7). However, while GBP1
14 resulted in low levels of mCherry in the HeLa cells, nE7 resulted in a roughly 3-fold
15 increase in mCherry, demonstrating that CPR is a powerful technique for detecting even
16 low cellular levels of a cellular target protein.

17

1

2

3 **Figure 7. Detecting an endogenous cancer marker using CPR.** HeLa cells are cancerous as a
 4 consequence of infection with HPV. These viral proteins provide a specific marker for HeLa cells that can
 5 be detected by nE7 nanobody (left). HEK293T cells do not contain this marker, and therefore no
 6 statistically significant difference is observed. For both cell types, median fluorescence is normalized to R-
 7 GBP1-mCherry fluorescence (background). Error bars represent 95% confidence intervals.

8

9 Discussion

10 We report here a new synthetic biology framework to elicit CPR based on proteomic
 11 information. To our knowledge, this is the first report that allows for the rescue of a target
 12 protein from degradation using a second protein as a masking agent. Although the initial
 13 feasibility was demonstrated using the SpyTag/SpyCatcher bioconjugation pair, even

non-covalent interactions can be used to achieve similar rescue efficiencies. The modularity of the design allows the addition of a UbL proteasome-targeting domain to eliminate background while still allowing rescue of a POI. The use of nanobodies as a small sensing domain removes the limit on the potential target pool and creates a new synthetic biology framework by allowing endogenous cellular proteins to decide the fate of a POI. We demonstrated this feasibility by detecting E7, a protein unique to HPV-positive cells. The availability of DDs with a wide range of degradation kinetics, including the N-end rule, offers the possibility to elicit rescue by an endogenous protein in a threshold-dependent manner. By combining different DDs and sensing domains, it may be possible to generate more complex, multi-input protein logic gates to help further differentiate between disease and healthy cells for therapeutic applications.

Materials and Methods

Plasmid construction: All constructs were prepared using standard molecular cloning techniques and cloned into pcDNA3.1(+) (Invitrogen). All oligonucleotides were ordered from Integrated DNA Technology (Coralville, IA) and purified via standard desalting. All enzymes were purchased from New England Biolabs (Ipswich, IA) and used per the manufacturer's protocol with the provided buffers. All overlapping oligos were first 5' phosphorylated with T4 polynucleotide kinase (PNK) treatment, and then were heat denatured and slow cooled to allow for proper hybridization before ligation.

mCherry:T2A:YFP-cODC1-SpyTag: YFP was PCR amplified and double digested with *AflIII* and *XhoI*. The DNA sequences for cODC1-SpyTag were ordered as overlapping

1 oligonucleotides as ultrameres with appropriate overhangs to make them complimentary
2 to *XhoI* and *ApaI*. The vector pcDNA3.1(+) was double digested with *AflIII* and *ApaI* to
3 generate the backbone, and YFP and cODC1-SpyTag were ligated simultaneously using
4 T4 DNA Ligase per the manufacturer's protocol to generate YFP-cODC1-SpyTag.
5 Finally, mCherry was PCR amplified with a reverse primer that included the T2A region
6 in the non-overlapping region, and this product was double digested with *NheI* and *AflIII*.
7 YFP-cODC1-SpyTag was double digested with *NheI* and *AflIII*, and mCherry:T2A was
8 ligated, generated mCherry:T2A:YFP-cODC1-SpyTag.

9

10 *SpyCatcher-mCherry:T2A:YFP-cODC1-SpyTag*: SpyCatcher was codon optimized and
11 ordered as a gBlock gene fragment. SpyCatcher was then PCR amplified and double
12 digested with *NheI* and *EcoRI*. mCherry:T2A was PCR amplified with the same reverse
13 primer as above, but the forward primer provided an N-terminal *EcoRI* site, and this
14 product was double digested with *EcoRI* and *AflIII*. mCherry:T2A:YFP-cODC1-SpyTag
15 was double digested with *NheI* and *AflIII* to remove mCherry:T2A and generate the
16 backbone into which SpyCatcher and mCherry:T2A were simultaneously ligated,
17 generating SpyCatcher-mCherry:T2A:YFP-cODC1-SpyTag.

18

19 *miRFP670 constructs*: miRFP670 was PCR amplified and double digested with *NheI*
20 and *HindIII*. The T2A polycistronic site was ordered as two overlapping oligonucleotides
21 with overhangs to provide *HindIII* and *AflIII* complimentary sites. mCherry:T2A:YFP-
22 cODC1-SpyTag was double digested with *NheI* and *AflIII* to remove mCherry:T2A.
23 miRFP670 and T2A were simultaneously ligated with the backbone to generate

1 miRFP670:T2A:YFP-cODC1-SpyTag. Next, miRFP670 was PCR amplified with
2 overhangs providing *EcoRI* and *HindIII* sites, and the product was double digested at
3 those sites. The human codon optimized SpyCatcher was PCR amplified and double
4 digested with *NheI* and *EcoRI* as described above. miRFP670:T2A:YFP-cODC1-SpyTag
5 was double digested with *NheI* and *HindIII* to remove miRFP670, and SpyCatcher and
6 miRFP670 was simultaneously ligated into the backbone, generating SpyCatcher-
7 miRFP670:T2A:YFP-cODC1-SpyTag. Finally, SH3 was PCR amplified. SH3 and
8 SpyCatcher-miRFP670:T2A:YFP-cODC1-SpyTag were double digested with *NheI* and
9 *EcoRI* to remove SpyCatcher, and SH3 was ligated to generate SH3-
10 miRFP670:T2A:YFP-cODC1-SpyTagSH3 and *SH3Lig* constructs. SH3 was PCR
11 amplified and double digested with *NheI* and *EcoRI*. SH3Lig was ordered as a pair of
12 overlapping oligonucleotides with overhangs providing for *XbaI* and *Apal*
13 complementation sites. Previous plasmids could be double digested with *NheI* and *EcoRI*
14 (to install SH3) or *XbaI* and *Apal* (to install SH3Lig) to generate SpyCatcher-
15 mCherry:T2A:YFP-cODC1-SH3Lig, SH3-mCherry:T2A:YFP-cODC1-SpyTag, or SH3-
16 mCherry:T2A:YFP-cODC1-SH3Lig.

17
18 *miRFP670-cODC1-SpyTag-GBP1*: SpyTag was ordered as a pair of overlapping
19 oligonucleotides providing overhangs with *XbaI* and *BamHI*. The GFP Nanobody
20 (GBP1), aka GFP Binding Protein 1 (GBP1), was PCR amplified and double digested
21 with *BamHI* and *Apal*. mCherry:T2A:YFP-cODC1-SpyTag was double digested with
22 *XbaI* *Apal* to remove SpyTag, and SpyTag and GBP1 were simultaneously ligated into
23 the backbone generating mCherry:T2A:YFP-cODC1-SpyTag-GBP1. Next, miRFP670

1 was PCR amplified and double digested with *AflIII* and *XhoI*, and mCherry:T2A:YFP-
2 cODC1-SpyTag-GBP1 was double digested with *XhoI* and *ApaI* in order to purify
3 cODC1-SpyTag-GBP1. pcDNA3.1(+) was double digested with *AflIII* and *ApaI*, and
4 miRFP670 and cODC1-SpyTag-GBP1 were simultaneously ligated into the vector to
5 generate miRFP670-cODC1-SpyTag-GBP1.

6

7 *yCD constructs:* BFP was PCR amplified and double digested with *NheI* and *Clal*. A
8 T2A site was ordered as overlapping ultramers with overhangs providing *Clal* and *AflIII*
9 complementation sites. mCherry:T2A:YFP-cODC1-SpyTag-GBP1 was double digested
10 with *NheI* and *AflIII* to remove mCherry:T2A. BFP and T2A were simultaneously ligated
11 into the cut vector to generate BFP:T2A:YFP-cODC1-SpyTag-GBP1. A second BFP was
12 PCR amplified and double digested with *EcoRI* and *Clal*. SH3 was again PCR amplified
13 similar to above and double digested with *NheI* and *EcoRI*. BFP:T2A:YFP-cODC1-
14 SpyTag-GBP1 was then double digested with *NheI* and *Clal*, and SH3 and BFP were
15 ligated to generate SH3-BFP:T2A:YFP-cODC1-SpyTag-GBP1. yCD was PCR amplified
16 and double digested with *AflIII* and *XhoI*. SH3-BFP:T2A:YFP-cODC1-SpyTag-GBP1
17 was also double digested with *AflIII* and *XhoI* to remove YFP, and yCD was ligated in its
18 place generating SH3-BFP:T2A:YFP-cODC1-SpyTag-GBP1. To generate the rescuing
19 construct, EGFP was PCR amplified and double digested with *NheI* and *EcoRI*. The
20 previous construct was double digested with the same enzymes to remove SH3, and GFP
21 was ligated in its place generating GFP-BFP:T2A:YFP-cODC1-SpyTag-GBP1.

22

1 *UbL constructs*: A single copy of the UbL domain was PCR amplified and double
2 digested with *AflIII* and *ClaI*. YFP was also PCR amplified and double digested with *ClaI*
3 and *XhoI*. Both mCherry:T2A:YFP-cODC1-SpyTag and SpyCatcher-
4 mCherry:T2A:YFP-cODC1-SpyTag were double digested with *AflIII* and *XhoI* to remove
5 YFP, and UbL and YFP were simultaneously ligated into the cut vector to generate
6 mCherry:T2A:UbL-YFP-cODC1-SpyTag and SpyCatcher-mCherry:T2A:UbL-YFP-
7 cODC1-SpyTag, respectively.

8
9 *N-end rule constructs*: Ub-R-GFP was a gift from Nico Dantuma (Addgene plasmid #
10 11939 ; <http://n2t.net/addgene:11939> ; RRID:Addgene_11939). Site directed
11 mutagenesis was performed to generate Ub M-GFP and Ub-L-GFP using Q5 Hot Start
12 High-Fidelity Polymerase New England Biolabs (Ipswich, IA) according to the
13 manufacture's protocol. KpnI and BamHI restriction sites were introduced via
14 mutagenesis between the N-terminal amino acid and GFP, and GBP1 was inserted into
15 these sites. Finally, GFP was excised using BamHI and NotI, and miRFP670 was ligated
16 in its place to generate Ub X-GBP1-miRFP670.

17
18 *LaM4 constructs*: To generate EGFP-cODC1-LaM4, EGFP was PCR amplified to include
19 AflIII and XhoI restriction sites. miRFP670-cODC1-GBP1 was digested with AflIII and
20 XhoI, and EGFP was ligated to generate EGFP-cODC1-GBP1. GBP1 was excised using
21 BamHI and ApaI, and LaM4 was ligated in its place. N-End rule constructs were
22 generated by excising GBP1 from Ub X-GBP1-EGFP using KpnI and BamHI; LaM4 was

1 ordered as a gene fragment and PCR amplified to include the same restriction sites, and
2 the ligation product yielded Ub X-LaM4-EGFP.

3

4 *nE7 constructs:* Ub R-GBP1-miRFP670 was digested with KpnI and BamHI. The nE7
5 nanobody was ordered as a gene fragment from IDT, PCR amplified to include KpnI and
6 BamHI restriction sites, and ligated into the vector. This subclone was subsequently
7 digested with AgeI and NotI, and mCherry was PCR amplified and cloned into place to
8 yield Ub R-nE7-mCherry. To generate the control construct, Ub R-GBP1-miRFP670 was
9 digested with AgeI and NotI, and mCherry was PCR amplified and ligated into the vector
10 to yield Ub R-GBP1-mCherry.

11

12 *Cell culture:* HeLa cells were maintained in T150 tissue culture flasks (Thermo Fisher) in
13 complete media, *i.e.* Minimum Essential Media (MEM, Cellgro) supplemented with 10%
14 fetal bovine serum (FBS, Corning), 10 U mL⁻¹ penicillin (HyClone), and 10 U mL⁻¹
15 streptomycin (HyClone) at 37°C and 5% CO₂. Cell passaging occurred upon reaching
16 confluency in the flask by treating with 0.05% trypsin-EDTA for 4 minutes at 37°C and
17 5% CO₂. Cells were pelleted at 500 g for 10 minutes, resuspended in 5 mL of complete
18 media, and counted. HeLa cells were seeded in 12-well plates at 175,000 cells/well and
19 6-well plates at 750,000 cells/well. HEK293T cells were seeded in 6-well plates at
20 250,000 cells/well.

21

22 *Transfection:* Plasmid DNA was prepared using ZymoPURE™ Plasmid Midiprep Kit
23 (Zymo Research) according to the manufacture's protocol. One day after seeding,

1 transfection was achieved with Lipofectamine® 3000 (Invitrogen) using 1 µg total
2 plasmid DNA per well for 6-well plates and 2.5 µg total plasmid DNA for 12-well plates
3 in complete media and following the manufacture’s protocol. Where more than one
4 plasmid was transfected, the total DNA was split evenly among all plasmids unless
5 otherwise noted.

6

7 *Fluorescent microscopy and image analysis:* All images were captured using an
8 Observer Z.1 Inverted Microscope (Zeiss) with GFP, mCherry, BFP, or Cy5 filter cube
9 sets (Chroma). For image analysis, five images were captured in each well. Image
10 analysis was conducted using the “Measure” analysis in ImageJ with threshold set 10-
11 255. Error bars on all plots represent the 95% confidence interval.

12

13 *Western blotting:* Following imaging, cells were incubated in ice-cold lysis buffer (50
14 mM Tris, 150 mM NaCl, 1% Triton X-100, pH 8.0) on ice for 20 minutes with protease
15 inhibitor cocktail (Calbiochem). Cells were then removed from the plate with a cell
16 scraper (Genemate), and the lysate was clarified in a pre-cooled centrifuge at 12,000
17 rpm for 10 minutes at 4°C. Total protein concentrations were normalized through a
18 Bradford assay (Bio-Rad) with a BSA standard. 15 µg of lysate was mixed with a 5x
19 loading buffer and separated by 10% SDS-PAGE before being transferred to a
20 nitrocellulose membrane (Bio-Rad).

21 Western blots were blocked in TBST (20 mM Tris, 500 mM NaCl, 0.05% Tween-
22 20, pH 8.0) containing 5% non-fat milk overnight at room temperature with gentle
23 shaking. Membranes were washed twice in TBST and incubated for 3 hours in anti-GFP

1 (1:5000 dilution, Covance) or anti-mCherry (1:2000 dilution, Novus) in TBS. The blots
2 were then washed twice in TBST and incubated with horseradish peroxidase (HRP)-
3 conjugated secondary antibody (GenScript) for 2 hours in TBST. The blots were washed
4 three times in TBST and developed using ECL reagents (GE) according to the
5 manufactures protocol. Band intensities were quantified using ImageJ gel analysis tools.

6

7 *Flow cytometry:* Most flow cytometry was conducted on the Novocyte Benchtop Flow
8 Cytometer (Acea Biosciences, San Diego, CA). Experiments involving mCherry (Ub R-
9 nE7-mCherry and Ub X-LaM4-EGFP rescued with mCherry) were conducted on BD
10 FACS Aria Fusion High Speed Cell Sorter (BD Biosciences, San Jose, CA). All flow
11 cytometry experiments involved $\geq 50,000$ transfected cells as determined by forward- and
12 side-scatter profiles of recorded events and fluorescent gating to exclude cells not
13 transfected by at least the rescuing protein for each respective experiment. Cells were
14 prepared for flow cytometry by washing twice in warm PBS. Trypsin treatment was
15 applied for 3 minutes, and the reaction was quenched by warm media. Cells were
16 collected in microcentrifuge tubes and spun at 0.8g for 5 minutes. The supernatant was
17 aspirated, and cells were resuspended in cold PBS. This solution was then passed
18 through a cell strainer into a flow cytometer tube and stored on ice until analysis.

19

20 *yCD viability studies:* HeLa cells were seeded as above in 6-well plates and transfected
21 with the appropriate constructs as above. Approximately one day post-transfection, wells
22 either received no treatment, 5-FC, or 5-FU for 48 hours. Viability was determined using

1 NucRed Dead 647 ReadyProbes Reagent (Thermo Fisher) per the manufacturer's
2 instruction. Fluorescent microscopy was used for analysis as described above.

3

4 *E7 detection studies:* HeLa cells and HEK293T cells were seeded as described above.
5 Transfection was conducted for 6 hours, and then replaced with normal media. Flow
6 cytometry analysis was conducted 24 hours post-transfection as described above.

7

8 *Statistical analysis:* All the experiments were performed in triplicates and results were
9 expressed as means $\pm$ standard deviations (SD). Statistical significance was analyzed
10 using the student *t*-tests. $P < 0.05$ was considered statistically significant throughout the
11 study.

12

13 **Acknowledgments**

14 This work was funded by grants from NSF (CBET1803008 and CBET1510817).

15

16 **The authors declare no conflict of interest.**

References

- Bachmair A, Finley D, Varshavsky A. 1986. In vivo half-life of a protein is a function of its amino-terminal residue. *Science* (80-) **234**:179–186. doi:10.1126/science.3018930
- Battle A, Khan Z, Wang SH, Mitran A, Ford MJ, Pritchard JK, Gilad Y. 2015. Impact of regulatory variation from RNA to protein. *Science* (80-) **347**:664–667. doi:10.1126/science.1260793
- Chen RP, Gaynor AS, Chen W. 2019. Synthetic biology approaches for targeted protein degradation. *Biotechnol Adv* **37**:107446. doi:10.1016/j.biotechadv.2019.107446
- Choi WS, Jeong B-C, Joo YJ, Lee M-R, Kim J, Eck MJ, Song HK. 2010. Structural basis for the recognition of N-end rule substrates by the UBR box of ubiquitin ligases. *Nat Struct Mol Biol* **17**:1175–81. doi:10.1038/nsmb.1907
- Chung HK, Jacobs CL, Huo Y, Yang J, Krumm SA, Plemper RK, Tsien RY, Lin MZ. 2015. Tunable and reversible drug control of protein production via a self-excising degron. *Nat Chem Biol* **11**:713–720. doi:10.1038/nchembio.1869
- Dueber JE, Mirsky EA, Lim WA. 2007. Engineering synthetic signaling proteins with ultrasensitive input/output control. *Nat Biotechnol* **25**:660–662. doi:10.1038/nbt1308
- Elsasser S, Gali RR, Schwickart M, Larsen CN, Leggett DS, Müller B, Feng MT, Tübing F, Dittmar GAG, Finley D. 2002. Proteasome subunit Rpn1 binds ubiquitin-like protein domains. *Nat Cell Biol* **4**:725–730. doi:10.1038/ncb845
- Fridy PC, Li Y, Keegan S, Thompson MK, Nudelman I, Scheid JF, Oeffinger M, Nussenzweig MC, Fenyö D, Chait BT, Rout MP. 2014. A robust pipeline for rapid production of versatile nanobody repertoires. *Nat Methods* **11**:1253–1260. doi:10.1038/nmeth.3170
- Gaynor AS, Chen W. 2017. Induced prodrug activation by conditional protein degradation. *J Biotechnol* **260**:62–66. doi:10.1016/j.jbiotec.2017.09.005
- Gonda DK, Bachmair A, Wunning I, Tobias JW, Lane WS, Varshavsky A. 1989. Universality and structure of the N-end rule. *J Biol Chem* **264**:16700–16712.
- Harper JW, Burton JL, Solomon MJ. 2002. The anaphase-promoting complex: it's not just for mitosis any more. *Genes Dev* **16**:2179–2206. doi:10.1101/gad.1013102
- Holst J, Burton AR, Vignali KM, Vignali DAA. 2006. Rapid analysis of T-cell selection in vivo using T cell-receptor retrogenic mice. *Nat Methods* **3**:191–197. doi:10.1038/nmeth858
- Iwamoto M, Björklund T, Lundberg C, Kirik D, Wandless TJ. 2010. A general chemical method to regulate protein stability in the mammalian central nervous system. *Chem Biol* **17**:981–988. doi:10.1016/j.chembiol.2010.07.009
- Jansma AL, Martinez-Yamout MA, Liao R, Sun P, Dyson HJ, Wright PE. 2014. The high-risk HPV16 E7 oncoprotein mediates interaction between the transcriptional coactivator CBP and the retinoblastoma protein pRb. *J Mol Biol* **426**:4030–4048. doi:10.1016/j.jmb.2014.10.021
- Jungbluth M, Renicke C, Taxis C. 2010. Targeted protein depletion in *Saccharomyces cerevisiae* by activation of a bidirectional degron. *BMC Syst Biol* **4**:176. doi:10.1186/1752-0509-4-176
- Kubala MH, Kovtun O, Alexandrov K, Collins BM. 2010. Structural and thermodynamic analysis of the GFP:GFP-nanobody complex. *Protein Sci* **19**:2389–2401.

doi:10.1002/pro.519

Lau HD, Yaegashi J, Zaro BW, Pratt MR. 2010. Precise control of protein concentration in living cells. *Angew Chemie - Int Ed* **49**:8458–8461. doi:10.1002/anie.201003073

Li S, Zhang W, Jiang K, Shan H, Shi M, Chen B, Hua Z. 2019. Nanobody against the E7 oncoprotein of human papillomavirus 16. *Mol Immunol* **109**:12–19. doi:10.1016/j.molimm.2019.02.022

Li SS. 2005. Specificity and versatility of SH3 and other proline-recognition domains: structural basis and implications for cellular signal transduction. *Biochem J* **390**:641–653. doi:10.1042/BJ20050411

Li X, Zhao X, Fang Y, Jiang X, Duong T, Fan C, Huang CC, Kain SR. 1998. Generation of destabilized green fluorescent protein as a transcription reporter. *J Biol Chem* **273**:34970–5.

Matta-Camacho E, Kozlov G, Li FF, Gehring K. 2010. Structural basis of substrate recognition and specificity in the N-end rule pathway. *Nat Struct Mol Biol* **17**:1182–1187. doi:10.1038/nsmb.1894

Mei L, Fan Y, Lv X, Welsh DK, Zhan C, Zhang EE. 2018. Long-term in vivo recording of circadian rhythms in brains of freely moving mice. *Proc Natl Acad Sci U S A* **115**:4276–4281. doi:10.1073/pnas.1717735115

Moody CA, Laimins LA. 2010. Human papillomavirus oncoproteins: Pathways to transformation. *Nat Rev Cancer*. doi:10.1038/nrc2886

Morgan DO. 1997. CYCLIN-DEPENDENT KINASES: Engines, Clocks, and Microprocessors. *Annu Rev Cell Dev Biol* **13**:261–291. doi:10.1146/annurev.cellbio.13.1.261

Oh J-H, Hyun J-Y, Varshavsky A. 2017. Control of Hsp90 chaperone and its clients by N-terminal acetylation and the N-end rule pathway. *Proc Natl Acad Sci U S A* **114**:E4379. doi:10.1073/pnas.1705898114

Polak A, Eschenhof E, Fernex M, Scholer HJ. 1976. Metabolic studies with 5-fluorocytosine-6-14C in mouse, rat, rabbit, dog and man. *Chemotherapy* **22**:137–53. doi:10.1159/000221923

Prakash S, Inobe T, Hatch AJ, Matouschek A. 2009. Substrate selection by the proteasome during degradation of protein complexes. *Nat Chem Biol* **5**:29–36. doi:10.1038/nchembio.130

Renicke C, Schuster D, Usherenko S, Essen LO, Taxis C. 2013. A LOV2 domain-based optogenetic tool to control protein degradation and cellular function. *Chem Biol* **20**:619–626. doi:10.1016/j.chembiol.2013.03.005

Saerens D, Pellis M, Loris R, Pardon E, Dumoulin M, Matagne A, Wyns L, Muyldermans S, Conrath K. 2005. Identification of a Universal VHH Framework to Graft Non-canonical Antigen-binding Loops of Camel Single-domain Antibodies. *J Mol Biol* **352**:597–607. doi:10.1016/j.jmb.2005.07.038

Senba M, Mori N. 2012. Mechanisms of virus immune evasion lead to development from chronic inflammation to cancer formation associated with human papillomavirus infection. *Oncol Rev* **6**:e17. doi:10.4081/oncol.2012.e17

Shcherbakova DM, Baloban M, Emelyanov A V, Brenowitz M, Guo P, Verkhusha V V. 2016. Bright monomeric near-infrared fluorescent proteins as tags and biosensors for multiscale imaging. *Nat Commun* **7**:12405. doi:10.1038/ncomms12405

Shemorry A, Hwang CS, Varshavsky A. 2013. Control of protein quality and

stoichiometries by N-terminal acetylation and the N-end rule pathway. *Mol Cell* **50**:540–551. doi:10.1016/j.molcel.2013.03.018 [doi]

Sherr CJ, Roberts JM. 1999. CDK inhibitors: positive and negative regulators of G1-phase progression. *Genes Dev* **13**:1501–12.

Sigoillot FD, King RW. 2011. Vigilance and Validation: Keys to Success in RNAi Screening. *ACS Chem Biol* **6**:47–60. doi:10.1021/cb100358f

Sjaastad LE, Fay EJ, Fiege JK, Macchietto MG, Stone IA, Markman MW, Shen S, Langlois RA. 2018. Distinct antiviral signatures revealed by the magnitude and round of influenza virus replication in vivo. *Proc Natl Acad Sci U S A* **115**:9610–9615. doi:10.1073/pnas.1807516115

Stack JH, Whitney M, Rodems SM, Pollok BA. 2000. A ubiquitin-based tagging system for controlled modulation of protein stability. *Nat Biotechnol* **18**:1298–1302. doi:10.1038/82422

Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, Vanin EF, Vignali DAA. 2004. Correction of multi-gene deficiency in vivo using a single “self-cleaving” 2A peptide-based retroviral vector. *Nat Biotechnol* **22**:589–594. doi:10.1038/nbt957

Tang JCY, Szikra T, Kozorovitskiy Y, Teixeira M, Sabatini BL, Roska B, Cepko CL. 2013. A nanobody-based system using fluorescent proteins as scaffolds for cell-specific gene manipulation. *Cell* **154**:928–939. doi:10.1016/j.cell.2013.07.021

Taxis C, Stier G, Spadaccini R, Knop M. 2009. Efficient protein depletion by genetically controlled deprotection of a dormant N-degron. *Mol Syst Biol* **5**:267. doi:10.1038/msb.2009.25

Vogel C, Marcotte EM. 2012. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. *Nat Rev Genet* **13**:227–232. doi:10.1038/nrg3185

Wu L, Candille SI, Choi Y, Xie D, Jiang L, Li-Pook-Than J, Tang H, Snyder M. 2013. Variation and genetic control of protein abundance in humans. *Nature* **499**:79–82. doi:10.1038/nature12223

Yu H, Gautam AKS, Wilmington SR, Wylie D, Martinez-Fonts K, Kago G, Warburton M, Chavali S, Inobe T, Finkelstein IJ, Babu MM, Matouschek A. 2016. Conserved Sequence Preferences Contribute to Substrate Recognition by the Proteasome. *J Biol Chem* **291**:14526–14539. doi:10.1074/jbc.M116.727578

Zakeri B, Fierer JO, Celik E, Chittock EC, Schwarz-Linek U, Moy VT, Howarth M. 2012. Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin. *Proc Natl Acad Sci U S A* **109**:E690–7. doi:10.1073/pnas.1115485109

Zhang J, Kale V, Chen M. 2014. Gene-Directed Enzyme Prodrug Therapy. *AAPS J* **17**:102–110. doi:10.1208/s12248-014-9675-7

Zhang Z, Kulkarni K, Hanrahan SJ, Thompson AJ, Barford D. 2010. The APC/C subunit Cdc16/Cut9 is a contiguous tetratricopeptide repeat superhelix with a homo-dimer interface similar to Cdc27. *EMBO J* **29**:3733–3744. doi:10.1038/emboj.2010.247 [doi]

a)

b)

a)

b)

c)